Gl261 tumors grown in CCL2-deficient mice or mice treated with a small-molecule antagonist of CCL-2 receptor, CCR4, failed to maximally accumulate Tregs and M-MDSCs within the glioma microenvironment [40]. This evidence concerns the gene CCL2 and central nervous system cancer.